Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.88 |
| ▸ | THRA | P10827 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239485 | 1.00 | POLB (0.88) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL7057797 | 0.98 | POLB (0.91) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL9429642 | 0.94 | POLB (1.00) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL5551950 | 0.87 | POLB (0.81) | POLBNPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL8626264 | 0.86 | ALDH1A1 (0.67) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL25269210 | 0.86 | ENPP2 (0.69) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL27909135 | 0.86 | ENPP2 (0.69) | POLBTHRATHRBNPC1RAB9A | |
| SCHEMBL11297385 | 0.85 | THRA (0.68) | POLBTHRATHRBSPHK1CA12 | |
| SCHEMBL6746649 | 0.85 | THRA (0.68) | POLBTHRATHRBSPHK1CA12 | |
| SCHEMBL3027338 | 0.85 | THRA (0.68) | POLBTHRATHRBSPHK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | POLB 4804/4885THRA 3607/4885THRB 3858/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | POLB 4439/4885THRA 441/4885THRB 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.